Positive Two-Year Data Boost Prospects For Vivus' Qnexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports continued weight loss advantage as well as improvement in weight-related co-morbidities, which has been a request from FDA's advisory committee.
You may also be interested in...
Arena Must Deal With Rat Neoplasms To Move Forward With Lorqess
A major task confronting Arena as it pursues approval of Lorqess is to provide FDA with an explanation that shows the neoplasms found in rats during animal studies of the obesity drug are not a predictor of cancer risk in humans.
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.
Qnexa May Get Staged Launch After No Vote From Advisory Committee
Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."